Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
2.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan8292. doi: 10.1126/scitranslmed.aan8292.

PMID:
29643232
3.

Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.

Steensma DP, Ebert BL.

N Engl J Med. 2018 Mar 29;378(13):1244-1245. doi: 10.1056/NEJMe1802610. No abstract available.

PMID:
29590545
4.

Christian Albert Theodor Billroth: Founder of Abdominal Surgery.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 Mar;93(3):e29-e30. doi: 10.1016/j.mayocp.2017.06.026. No abstract available.

PMID:
29502575
5.

Prognosis in myelodysplastic syndromes: The attractions and limitations of simplicity.

Steensma DP.

Am J Hematol. 2018 May;93(5):605-606. doi: 10.1002/ajh.25068. Epub 2018 Feb 26. No abstract available.

PMID:
29451319
6.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
7.

The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Ghobrial IM, Detappe A, Anderson KC, Steensma DP.

Nat Rev Clin Oncol. 2018 Apr;15(4):219-233. doi: 10.1038/nrclinonc.2017.197. Epub 2018 Jan 9. Review.

PMID:
29311715
8.

Álvaro Alvim-Radiologist and Brazilian "Martyr to Science".

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2018 Jan;93(1):e7. doi: 10.1016/j.mayocp.2017.06.025. No abstract available.

PMID:
29304925
9.

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT.

Blood Adv. 2017 Oct 18;1(23):2032-2040. doi: 10.1182/bloodadvances.2017010165. eCollection 2017 Oct 24.

10.

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia.

Morgan EA, Lee MN, DeAngelo DJ, Steensma DP, Stone RM, Kuo FC, Aster JC, Gibson CJ, Lindsley RC.

Blood Adv. 2017 Sep 13;1(21):1786-1789. doi: 10.1182/bloodadvances.2017011197. eCollection 2017 Sep 26. No abstract available.

11.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G.

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. No abstract available.

12.

The Raven.

Steensma DP.

J Clin Oncol. 2018 Feb 10;36(5):512-513. doi: 10.1200/JCO.2017.76.3458. Epub 2017 Dec 13. No abstract available.

PMID:
29236583
13.

The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.

Steensma DP.

Best Pract Res Clin Haematol. 2017 Dec;30(4):295-300. doi: 10.1016/j.beha.2017.09.009. Epub 2017 Sep 22. Review.

PMID:
29156198
14.

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK.

Am J Hematol. 2018 Feb;93(2):254-261. doi: 10.1002/ajh.24968. Epub 2017 Nov 21.

PMID:
29119643
15.

Thalassemia and Thomas Benton Cooley.

Siddiqui S, Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Nov;92(11):e161-e162. doi: 10.1016/j.mayocp.2017.06.024. Epub 2017 Nov 1. No abstract available.

PMID:
29101943
16.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

17.

Charles Fletcher, The Centaur Company, and Proprietary Medicine Revenue Stamps.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Sep;92(9):e127-e128. doi: 10.1016/j.mayocp.2017.06.021. No abstract available.

PMID:
28870369
18.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G.

Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

PMID:
28774880
19.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

PMID:
28759108
20.

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?

Zeidan AM, Sekeres MA, Barnard J, Steensma DP, Komrokji R.

Leukemia. 2017 Nov;31(11):2539-2541. doi: 10.1038/leu.2017.238. Epub 2017 Jul 31. No abstract available.

PMID:
28757618
21.

Adolf Lorenz - The Bloodless Surgeon of Vienna.

Afshar A, Kyle RA, Steensma DP.

Mayo Clin Proc. 2017 Jul;92(7):e105-e106. doi: 10.1016/j.mayocp.2017.02.025. No abstract available.

PMID:
28688475
22.

Antonius Mathijsen and Plaster Casts.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 May;92(5):e83. doi: 10.1016/j.mayocp.2017.01.028. No abstract available.

PMID:
28473048
23.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
24.

The origin and evolution of the term "clone".

Steensma DP.

Leuk Res. 2017 Jun;57:97-101. doi: 10.1016/j.leukres.2017.03.004. Epub 2017 Mar 4.

PMID:
28340380
25.

Self-reported sleep disturbance and survival in myelodysplastic syndromes.

Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA.

Br J Haematol. 2017 May;177(4):562-566. doi: 10.1111/bjh.14573. Epub 2017 Mar 8.

PMID:
28272741
26.

Van Gogh's Portrait of Dr Gachet.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Mar;92(3):e57-e58. doi: 10.1016/j.mayocp.2016.10.024. No abstract available.

PMID:
28259236
27.

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R.

Leukemia. 2017 Jun;31(6):1391-1397. doi: 10.1038/leu.2017.33. Epub 2017 Jan 23.

PMID:
28111463
28.

The Medical Doctors of Star Trek: Leonard "Bones" McCoy and Beverly Crusher.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2017 Jan;92(1):e9-e10. doi: 10.1016/j.mayocp.2016.10.025. No abstract available.

PMID:
28062069
29.

Conventional cytogenetics for myeloid neoplasms in the era of next-generation-sequencing.

Kuo FC, Steensma DP, Dal Cin P.

Am J Hematol. 2017 Mar;92(3):227-229. doi: 10.1002/ajh.24642. No abstract available.

30.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

31.

Predicting therapy-related myeloid neoplasms-and preventing them?

Steensma DP.

Lancet Oncol. 2017 Jan;18(1):11-13. doi: 10.1016/S1470-2045(16)30622-2. Epub 2016 Dec 4. No abstract available.

PMID:
27927581
32.

Hendrik van Deventer: Dutch Obstetrician and Orthopedist.

Steensma DP, Kyle RA.

Mayo Clin Proc. 2016 Dec;91(12):e171. doi: 10.1016/j.mayocp.2016.10.017. No abstract available.

PMID:
27916164
33.

New challenges in evaluating anemia in older persons in the era of molecular testing.

Steensma DP.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):67-73. Review.

PMID:
27913464
34.

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.

Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM.

Transfusion. 2017 Feb;57(2):289-295. doi: 10.1111/trf.13934. Epub 2016 Nov 22.

35.

Good riddance to the term "refractory anemia" in myelodysplastic syndromes.

Steensma DP.

Leuk Res. 2016 Dec;51:22-26. doi: 10.1016/j.leukres.2016.10.007. Epub 2016 Oct 17.

PMID:
27776290
36.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA; Evans MDS Clinical Research Consortium.

Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24.

37.

The importance of erythroblast enumeration in myeloid neoplasia.

Zeidan AM, Xu M, Steensma DP.

Ann Hematol. 2017 Feb;96(2):329-330. doi: 10.1007/s00277-016-2862-0. Epub 2016 Oct 23. No abstract available.

PMID:
27771743
38.

Staunching the rising costs of haematological health care.

Ruiz-Argüelles GJ, Steensma DP.

Lancet Haematol. 2016 Oct;3(10):e455. doi: 10.1016/S2352-3026(16)30127-2. No abstract available.

PMID:
27692304
39.

Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.

Bhatt VR, Steensma DP.

J Oncol Pract. 2016 Sep;12(9):786-92. doi: 10.1200/JOP.2016.015214. Review.

PMID:
27621329
40.

Putting it all together in CMML risk stratification.

Steensma DP.

Blood. 2016 Sep 8;128(10):1318-9. doi: 10.1182/blood-2016-07-727800. No abstract available.

41.

J. Robin Warren: Helicobacter Pylori and Peptic Ulcer.

Steensma DP, Kyle RA, Shampo MA.

Mayo Clin Proc. 2016 Sep;91(9):e129-30. doi: 10.1016/j.mayocp.2016.01.027. No abstract available.

PMID:
27594194
42.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H.

BMC Cancer. 2016 Aug 19;16:652. doi: 10.1186/s12885-016-2710-6.

43.

Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.

Brierley CK, Steensma DP.

Curr Hematol Malig Rep. 2016 Dec;11(6):408-415. doi: 10.1007/s11899-016-0344-z. Review.

PMID:
27492253
44.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

45.

Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP.

Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15.

46.

Elizabeth Blackburn and Maintenance of Telomeres.

Steensma DP, Kyle RA, Shampo MA.

Mayo Clin Proc. 2016 Jul;91(7):e105. doi: 10.1016/j.mayocp.2016.01.026. No abstract available.

PMID:
27378050
47.

Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis.

El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, Hobbs G, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS.

Lancet Haematol. 2016 Jun;3(6):e276-83. doi: 10.1016/S2352-3026(16)30024-2. Epub 2016 May 18.

PMID:
27264037
48.

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.

Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, Ballen KK.

Cancer. 2016 Aug 1;122(15):2379-88. doi: 10.1002/cncr.30037. Epub 2016 May 12.

49.

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.

Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, Stone RM.

Am J Hematol. 2016 Aug;91(8):793-9. doi: 10.1002/ajh.24410. Epub 2016 Jun 3.

50.

Barry James Marshall-Discovery of Helicobacter pylori as a Cause of Peptic Ulcer.

Kyle RA, Steensma DP, Shampo MA.

Mayo Clin Proc. 2016 May;91(5):e67-8. doi: 10.1016/j.mayocp.2016.01.025. No abstract available.

PMID:
27150219

Supplemental Content

Loading ...
Support Center